① After receiving treatment with Wegovy, weight loss was more obvious, and the incidence of serious adverse events was lower; ② Wegovy not only showed treatment results, but also was well tolerated, which meant that patients could withstand this treatment well without serious side effects.
Finance Association, April 7 (Editor Niu Zhanlin) A recent study shows that$Novo-Nordisk A/S (NVO.US)$Its “weight loss elixir” Wegovy (the main ingredient is simeglutide) can not only lose weight, but also benefit the health of patients with diabetes and heart failure.
The report, published in the medical journal “New England Journal of Medicine” on Saturday (April 6), said that for patients with heart failure, especially those with obese heart failure (HFpEF) patients with preserved ejection scores, weight loss was more obvious after receiving Wegovy treatment, and the incidence of serious adverse events was lower.
This type of heart failure severely limits a person's ability to participate in everyday life. Patients are often prone to fatigue and breathing difficulties, which can result in a high risk of hospitalization, disability, and death.
Current treatments for HFpEF include lifestyle changes and heart disease medications, but there are no treatments specifically approved to treat HFpEF, and the number of people with this condition has been increasing significantly.
Last fall, researchers released research showing that Wegovy has significant positive health effects on people with this heart disease, but later they want to see if Wegovy also has effects on patients with both type 2 diabetes and HFpEF.
In the latest study, the researchers randomly divided 616 patients with type 2 diabetes and HFpEF into two groups. The patients came from 16 countries and all had a body mass index (BMI) above 30. One group took Wegovy and the other group took a placebo.
The researchers followed the two groups of patients for a year. The conclusion was that compared to patients taking placebo, patients treated with Wegovy had significantly better results in reducing weight loss, heart failure-related symptoms, and physical limitations. Additionally, these patients were able to go further during the six-minute walk test and also improved biomarkers of inflammation and other issues.
In terms of adverse events, the Wegovy treatment group reported 55 serious adverse events and the placebo group reported 88 cases. In terms of deaths, 6 people died in the Wegovy group and 10 in the placebo group. The deaths related to central vascular problems were 1 in the Wegovy group and 4 in the placebo group.
Dr. Mikhail Kosiborod, a researcher and cardiologist at the St. Luke's Central American Heart Institute, said that the consistent results of the latest research and the study published last year seem to suggest that Wegovy is an effective and safe treatment option for a wide range of people, including diabetics.
On Saturday, Kosiborod also presented the study to the American College of Cardiology. He thought the findings were very exciting because heart failure patients are often difficult to treat, and the number of such patients is increasing. But now, Wegovy has not only shown results, but is well tolerated, which means that patients can withstand this treatment well without serious side effects.
Editor/Somer